ArticleCancer immunology, immunotherapy : CII2003
CD26 expression determines lung metastasis in mutant F344 rats: involvement of NK cell function and soluble CD26.
Article in Cancer immunology, immunotherapy : CII, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 39 citations in OpenAlex.
- The role of DPP4 in viral infections: from receptor biology to antiviral target.Archives of virology · 2026Review
- Integrative pan-cancer analysis of dipeptidyl peptidase 4 with clinical andFrontiers in immunology · 2026Article
- Revolutionizing Treatment Strategies for Autoimmune and Inflammatory Disorders: The Impact of Dipeptidyl-Peptidase 4 Inhibitors.Journal of inflammation research · 2024Review
- Emerging Role of Dipeptidyl Peptidase-4 in Autoimmune Disease.Frontiers in immunology · 2022 · on this mapReview
- Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence.Nature reviews. Nephrology · 2021Review
- The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence.Frontiers in pharmacology · 2021Review
- Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions.Pharmacology & therapeutics · 2020Review
- Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.Clinical and experimental immunology · 2016Review
- Suppression of lung metastases by the CD26/DPP4 inhibitor Vildagliptin in mice.Clinical & experimental metastasis · 2015Article
- The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis.Frontiers in immunology · 2015Review
- Serum calprotectin, CD26 and EGF to establish a panel for the diagnosis of lung cancer.PloS one · 2015Article
- Dipeptidyl peptidase IV as a potential target for selective prodrug activation and chemotherapeutic action in cancers.Molecular pharmaceutics · 2014Article
- Exendin-4 induces cell adhesion and differentiation and counteracts the invasive potential of human neuroblastoma cells.PloS one · 2013Article
- Potential of soluble CD26 as a serum marker for colorectal cancer detection.World journal of clinical oncology · 2011Article
- On the origin of serum CD26 and its altered concentration in cancer patients.Cancer immunology, immunotherapy : CII · 2009Review
- CD26/dipeptidyl peptidase 4-deficiency alters thymic emigration patterns and leukcocyte subsets in F344-rats age-dependently.Clinical and experimental immunology · 2009Article
- Regulation of expression and function of dipeptidyl peptidase 4 (DP4), DP8/9, and DP10 in allergic responses of the lung in rats.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2008Article
- CD26 (dipeptidyl-peptidase IV)-dependent recruitment of T cells in a rat asthma model.Clinical and experimental immunology · 2005Article
- Cell-surface peptidases.International review of cytology · 2004Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The association between CD26 expression, tumor cell adhesion, metastasis, and natural killer (NK) cell function was investigated in a CD26 mutant Fischer 344 (F344/DuCrj) substrain from Japanese breeders (F344JAP) in comparison with wild-type F344 substrains from US (F344/Crl) and Hannover (HAN; F344/Ztm) breeders. F344JAP rats lack the dipeptidyl peptidase IV activity of CD26 and show a reduced cell surface expression of the mutated CD26 glycoprotein. In vivo adhesion of vital dye-labeled MADB106 tumor cells, tumor colonization, CD26 enzymatic activity, and CD26 immunoreactivity in lungs and soluble CD26-like protein expression in serum were markedly reduced in F344JAP rats. These findings demonstrate that CD26 protein expression exerts a key role in lung metastasis. In addition, NK cell cytotoxicity against MADB106 cells was diminished in the mutant F344 substrain, suggesting that CD26 enzymatic activity sustains NK cytotoxicity. Interestingly, tumor cells lacked CD26 immunoreactivity in vitro, but displayed CD26 immunoreactivity in situ after in vivo inoculation as well as after incubation with rat serum, indicating that soluble CD26-like protein assembles in tumor cells during in vivo passage, which may interact with the process of tumor adhesion and metastasis. Overall, these findings indicate that altered expression and function of a single enzyme-the CD26 protein--can drastically change the outcome of metastatic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.